Liraglutide, sold most widely as Saxenda / Victoza, is a GLP-1 receptor agonist used for weight management and type 2 diabetes. This guide covers how it works, what a standard course looks like, and how ShiningRX supplies it to trade buyers and consumers in the USA, UK and Australia.
Key takeaways
- Liraglutide is a GLP-1 receptor agonist indicated for weight management and type 2 diabetes.
- Typical dosing: daily injection titrated weekly from 0.6 mg to 3.0 mg.
- Onset is appetite effect within the first week; effect lasts 24 hours, daily dosing.
- Most reported side effects are nausea and other mild, self-limiting reactions.
- Store 2–8 °C cold chain until first use.
Liraglutide at a glance
| Attribute | Detail |
|---|---|
| Drug class | GLP-1 receptor agonist |
| Common brand | Saxenda / Victoza |
| Licensed use | weight management and type 2 diabetes |
| Available strengths | 6 mg/mL multi-dose pen |
| Dosage form | prefilled pen |
| Typical onset | appetite effect within the first week |
| Duration / dosing interval | 24 hours, daily dosing |
| Storage | 2–8 °C cold chain until first use |
How Liraglutide works
As a GLP-1 receptor agonist, Liraglutide acts on the pathway that drives weight management and type 2 diabetes. The pharmacological effect is dose-related, which is why prescribers begin at the lowest useful strength and adjust on response rather than starting at the maximum. In practice that means daily injection titrated weekly from 0.6 mg to 3.0 mg
Starting a Liraglutide course
- 1
Clinical assessment
Confirm the indication for weight management and type 2 diabetes, review comorbidities and check the contraindication list before the first dose.
- 2
Initiate at the standard dose
daily injection titrated weekly from 0.6 mg to 3.0 mg
- 3
Review at the first checkpoint
Reassess once the expected onset window of appetite effect within the first week has passed and document tolerability.
- 4
Titrate or switch
If response is partial and tolerance is good, step up within the licensed range; if tolerance is poor, consider Semaglutide.
Safety profile in brief
Commonly reported effects include nausea, vomiting, headache, hypoglycaemia with insulin. Liraglutide should be avoided in MTC/MEN2 history, severe gastroparesis. Any severe, persistent or unexpected reaction warrants stopping the medicine and seeking clinical review.